Related Experiment Videos
Doses and models in risk assessment analysis for bronchial hyperresponsiveness
R de Marco1, M Bugiani, E Zanolin
1Cattedra di Statistica Medica e Biometria, Università di Verona, Italy.
Journal of Clinical Epidemiology
|February 19, 1998
Summary
This study found that 2 mg of methacholine is sufficient to identify risk factors for bronchial hyperresponsiveness (BHR). Weibull regression proved more effective than traditional models for analyzing BHR dose-response curves.
Area of Science:
- Pulmonology
- Epidemiology
- Biostatistics
Background:
- Bronchial hyperresponsiveness (BHR) is a key feature of asthma and other respiratory diseases.
- Identifying risk factors for BHR is crucial for understanding disease pathogenesis and developing targeted interventions.
Purpose of the Study:
- To assess if risk factor associations with BHR vary based on the cumulative dose in challenge tests.
- To determine the suitability of Weibull regression for analyzing methacholine dose-response curves.
Main Methods:
- Analysis of 863 methacholine challenge tests from the EC Respiratory Health Survey in Italy.
- Comparison of Weibull regression with logistic and linear models, using data truncated at 2 mg and up to 6 mg cumulative dose.
Main Results:
- Respiratory symptoms and atopy were identified as primary risk factors for BHR across all methods.
- Age and airway caliber demonstrated a protective effect against BHR.
- A cumulative dose of 2 mg methacholine was found sufficient to assess risk factor effects in epidemiological surveys.
Conclusions:
- The Weibull regression model provided a better explanation of variability in methacholine dose-response curves compared to linear and logistic models.
- The findings support the use of 2 mg methacholine as an adequate cumulative dose for BHR risk factor assessment in epidemiological studies.